Stephani Correia Brazão

Stephani Correia Brazão

Auto-generated profile, based on publicly available information

Stephani Correia Brazão

Laboratory of Experimental Pharmacology (LAFE), Department of Physiology and Pharmacology, Biomedical Institute, Fluminense Federal University (UFF), Niteroi, RJ, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Toxicology
Verified
Journal Article
Closed access
AMAna Beatriz Araújo Mendes
Ana Beatriz Araújo Mendes
NMNadia Alice Vieira Motta
Nadia Alice Vieira Motta
GLGabriel Ferreira Lima
Gabriel Ferreira Lima
LALis Jappour Autran
Lis Jappour Autran
SBStephani Correia Brazão
Stephani Correia Brazão
FBFernanda Carla Ferreira Brito
Fernanda Carla Ferreira Brito

22 February 2021 in International Journal of Cardiovascular Sciences
Verified
Journal Article
Closed access
PDF file
SBStephani Correia Brazão
Stephani Correia Brazão
LALis Jappour Autran
Lis Jappour Autran
RLRosane de Oliveira Lopes
Rosane de Oliveira Lopes
CSCHRISTIANNE BRETAS VIEIRA SCARAMELLO
CHRISTIANNE BRETAS VIEIRA SCARAMELLO
FBFernanda Carla Ferreira de Brito
Fernanda Carla Ferreira de Brito
NMNadia Alice Vieira Motta
Nadia Alice Vieira Motta
Chloroquine (CQ) and Hydroxychloroquine (HCQ) are antimalarial drugs, with anti-inflammatory properties that justify their use in the treatment of systemic lupus erythematosus and rheumatic diseases. A pandemic caused by the new coronavirus led the entire world’s scientific community to look for drugs already available on the market, capable of exercising beneficial actions in the fight against the disease. Preliminary studies in patients, as well as in vitro studies, suggested possible therapeutic effects associated with the use of HCQ and [...] Abstract Chloroquine (CQ) and Hydroxychloroquine (HCQ) are antimalarial drugs, with anti-inflammatory properties that justify their use in the treatment of systemic lupus erythematosus and rheumatic diseases. A pandemic caused by the new coronavirus led the entire world’s scientific community to look for drugs already available on the market, capable of exercising beneficial actions in the fight against the disease. Preliminary studies in patients, as well as in vitro studies, suggested possible therapeutic effects associated with the use of HCQ and